RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Summary

This Phase II open label study will evaluate the safety and efficacy of repeat doses of RGI-2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT). These subjects will be compared to contemporary controls.

Timeline

Start

2019-11-25

Primary completion

2022-07-05

Completion

2023-04-03

Publications

• DeFilipp Z, Choe H, Efebera YA, Saad A, Farhan S, Lekakis L, Yared JA, Schiller G, Mapara MY, Assal A, Gooley T, Bui JD, Lee D, Lane H, Chen YB. RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT. Blood. 2025 Oct 23;146(17):2037-2046. doi: 10.1182/blood.2025029584.

Drugs

Indications